Virginia Cancer Specialists

Recent papers from Virginia Cancer Specialists

1. Normalized membrane ratio of TROP2 as a predictor of clinical outcomes with datopotamab deruxtecan in non-small-cell lung cancerNature Medicine · 2026
2. Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi studyFuture Oncology · 2026
3. Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumorsFuture Oncology · 2026
4. A Pacemaker Feeling the HeatJACC Case Reports · 2026
5. Giredestrant plus Everolimus in Advanced Breast CancerNew England Journal of Medicine · 2026
6. Impact of Radiation Therapy on Physical and Psychosocial Health of Adolescents and Young Adults: A Joint Report From the Children's Oncology Group AYA and Radiation Oncology CommitteesPediatric Blood & Cancer · 2026
7. Daraxonrasib for Previously Treated RAS -Mutant Non–Small-Cell Lung CancerNew England Journal of Medicine · 2026
8. Perioperative Durvalumab for Resectable Non–Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN TrialJournal of Clinical Oncology · 2026
9. Summary of Research: Brentuximab Vedotin and Nivolumab in Combination with Chemotherapy for Nonbulky, Early-Stage Classical Hodgkin LymphomaAdvances in Therapy · 2026
10. Can Orthopaedic Oncologists Agree on What Is and Is Not a Pathologic Fracture?Clinical Orthopaedics and Related Research · 2026
11. Plain language summary of subcutaneous vs IV amivantamab plus lazertinib in EGFR -altered non-small-cell lung cancerFuture Oncology · 2026
12. From technology transfer to systems transformation: CGIAR's ways of working through a just transition lensOutlook on Agriculture · 2026
13. Acquired resistance to the RAS(ON) multi-selective inhibitor daraxonrasib guides rational combination therapy strategies in pancreatic cancerNature Medicine · 2026
14. AdvanTIG-301: a phase III study of ociperlimab plus tislelizumab and concurrent chemoradiotherapy in stage III unresectable non-small cell lung cancerJournal for ImmunoTherapy of Cancer · 2026
15. Early Acute Leukemia Relapse After CD19‐Directed CAR‐T With Lineage Switch From B to T‐ALL in a Pediatric PatientPediatric Blood & Cancer · 2026
16. Vobramitamab duocarmazine, an anti–B7‐H3 antibody–drug conjugate, in patients with advanced solid tumors: Final results of a phase 1 cohort expansionCancer · 2026
17. Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summaryFuture Oncology · 2026
18. 169TiP A phase I first-in-human, open-label study evaluating safety, pharmacokinetics, and efficacy of ABBV-901 as monotherapy and in combination with bevacizumab (Bev) in adult patients with platinum-resistant ovarian cancer (PROC)ESMO Open · 2026
19. AdvanTIG-302: Phase 3 Study of Ociperlimab (Anti-TIGIT) Plus Tislelizumab (Anti–PD-1) Versus Pembrolizumab in Untreated, Locally Advanced, Unresectable, or Metastatic NSCLC With PD-L1 Expression of 50% or MoreJournal of Thoracic Oncology · 2026
20. Metastatic Vaginal Melanoma: A Case ReportJournal of Current Oncology · 2026